Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891069722> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2891069722 abstract "3016 Background: Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) substantially improve patient survival in clear-cell renal cell carcinoma (ccRCC), but predictive biomarkers for efficacy have not yet been identified. Methods: We analyzed whole exome sequencing (WES) from a clinical trial of anti-PD-1 monotherapy (nivolumab) for ccRCC (N = 34) to discover genomic predictors of response to immune checkpoint therapy, and validated our findings in 28 ccRCC patients from 2 institutions treated with anti-PD-1 or anti-PD-L1 therapies. We defined 3 response groups: clinical benefit (CB) – complete or partial response by RECIST or stable disease with objective decrease in tumor burden and progression free survival (PFS) > 6 months - and no clinical benefit (NCB) – progressive disease with PFS < 3 months, with all other patients in intermediate benefit (IB). We further validated our findings in WES from 212 melanoma patients treated with immune checkpoint therapies in 3 published cohorts. Results: Biallelic loss of the chromatin remodeling subunit PBRM1, mutated in 34/62 (55%) patients across both cohorts and up to 41% of ccRCC overall, was the only gene mutation associated with CB in both the training (p = 0.0064; Pearson’s chi-squared) and validation cohorts (p = 0.043), and predicted both PFS and overall survival (OS) (p = 0.042 and 0.014, respectively; Kaplan-Meier). In 212 melanomas, truncating alterations in ARID2 – a closely related chromatin remodeler - were also enriched in responders after correcting for tumor mutational burden (p = 0.036), and having a truncating alteration in either PBRM1 or ARID2 significantly predicted overall survival (p = 0.022). In this ccRCC cohort, tumor mutational burden and loss of antigen presentation machinery were not associated with CB or NCB. Conclusions: Loss of chromatin remodeling subunits may impact response to immune checkpoint therapy in both ccRCC and melanoma. Further study in larger cohorts of immunotherapy-treated patients and functional characterization of ARID2 and PBRM1 in the context of the tumor-immune microenvironment will help to determine potential for further biomarker development." @default.
- W2891069722 created "2018-09-27" @default.
- W2891069722 creator A5003084219 @default.
- W2891069722 creator A5003161204 @default.
- W2891069722 creator A5023841393 @default.
- W2891069722 creator A5029218279 @default.
- W2891069722 creator A5029805571 @default.
- W2891069722 creator A5031810877 @default.
- W2891069722 creator A5039044023 @default.
- W2891069722 creator A5042777250 @default.
- W2891069722 creator A5046795494 @default.
- W2891069722 creator A5052504518 @default.
- W2891069722 creator A5056181905 @default.
- W2891069722 creator A5059063118 @default.
- W2891069722 creator A5088186279 @default.
- W2891069722 creator A5091176592 @default.
- W2891069722 creator A5091859782 @default.
- W2891069722 date "2017-05-20" @default.
- W2891069722 modified "2023-09-24" @default.
- W2891069722 title "Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma." @default.
- W2891069722 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.3016" @default.
- W2891069722 hasPublicationYear "2017" @default.
- W2891069722 type Work @default.
- W2891069722 sameAs 2891069722 @default.
- W2891069722 citedByCount "4" @default.
- W2891069722 countsByYear W28910697222018 @default.
- W2891069722 countsByYear W28910697222019 @default.
- W2891069722 countsByYear W28910697222020 @default.
- W2891069722 countsByYear W28910697222021 @default.
- W2891069722 crossrefType "journal-article" @default.
- W2891069722 hasAuthorship W2891069722A5003084219 @default.
- W2891069722 hasAuthorship W2891069722A5003161204 @default.
- W2891069722 hasAuthorship W2891069722A5023841393 @default.
- W2891069722 hasAuthorship W2891069722A5029218279 @default.
- W2891069722 hasAuthorship W2891069722A5029805571 @default.
- W2891069722 hasAuthorship W2891069722A5031810877 @default.
- W2891069722 hasAuthorship W2891069722A5039044023 @default.
- W2891069722 hasAuthorship W2891069722A5042777250 @default.
- W2891069722 hasAuthorship W2891069722A5046795494 @default.
- W2891069722 hasAuthorship W2891069722A5052504518 @default.
- W2891069722 hasAuthorship W2891069722A5056181905 @default.
- W2891069722 hasAuthorship W2891069722A5059063118 @default.
- W2891069722 hasAuthorship W2891069722A5088186279 @default.
- W2891069722 hasAuthorship W2891069722A5091176592 @default.
- W2891069722 hasAuthorship W2891069722A5091859782 @default.
- W2891069722 hasConcept C104317684 @default.
- W2891069722 hasConcept C105951970 @default.
- W2891069722 hasConcept C121608353 @default.
- W2891069722 hasConcept C126322002 @default.
- W2891069722 hasConcept C127716648 @default.
- W2891069722 hasConcept C143998085 @default.
- W2891069722 hasConcept C159641895 @default.
- W2891069722 hasConcept C185592680 @default.
- W2891069722 hasConcept C2777472916 @default.
- W2891069722 hasConcept C2777701055 @default.
- W2891069722 hasConcept C2781053074 @default.
- W2891069722 hasConcept C502942594 @default.
- W2891069722 hasConcept C55493867 @default.
- W2891069722 hasConcept C71924100 @default.
- W2891069722 hasConceptScore W2891069722C104317684 @default.
- W2891069722 hasConceptScore W2891069722C105951970 @default.
- W2891069722 hasConceptScore W2891069722C121608353 @default.
- W2891069722 hasConceptScore W2891069722C126322002 @default.
- W2891069722 hasConceptScore W2891069722C127716648 @default.
- W2891069722 hasConceptScore W2891069722C143998085 @default.
- W2891069722 hasConceptScore W2891069722C159641895 @default.
- W2891069722 hasConceptScore W2891069722C185592680 @default.
- W2891069722 hasConceptScore W2891069722C2777472916 @default.
- W2891069722 hasConceptScore W2891069722C2777701055 @default.
- W2891069722 hasConceptScore W2891069722C2781053074 @default.
- W2891069722 hasConceptScore W2891069722C502942594 @default.
- W2891069722 hasConceptScore W2891069722C55493867 @default.
- W2891069722 hasConceptScore W2891069722C71924100 @default.
- W2891069722 hasLocation W28910697221 @default.
- W2891069722 hasOpenAccess W2891069722 @default.
- W2891069722 hasPrimaryLocation W28910697221 @default.
- W2891069722 hasRelatedWork W2516455201 @default.
- W2891069722 hasRelatedWork W2527963736 @default.
- W2891069722 hasRelatedWork W2747856781 @default.
- W2891069722 hasRelatedWork W2796838039 @default.
- W2891069722 hasRelatedWork W2804441916 @default.
- W2891069722 hasRelatedWork W2892005194 @default.
- W2891069722 hasRelatedWork W2916292904 @default.
- W2891069722 hasRelatedWork W2920936787 @default.
- W2891069722 hasRelatedWork W2921726352 @default.
- W2891069722 hasRelatedWork W2936523734 @default.
- W2891069722 hasRelatedWork W2947426270 @default.
- W2891069722 hasRelatedWork W2947942432 @default.
- W2891069722 hasRelatedWork W3029753758 @default.
- W2891069722 hasRelatedWork W3031088940 @default.
- W2891069722 hasRelatedWork W3034482678 @default.
- W2891069722 hasRelatedWork W3107429554 @default.
- W2891069722 hasRelatedWork W3166211548 @default.
- W2891069722 hasRelatedWork W3171242356 @default.
- W2891069722 hasRelatedWork W3181277240 @default.
- W2891069722 hasRelatedWork W3202611673 @default.
- W2891069722 isParatext "false" @default.
- W2891069722 isRetracted "false" @default.
- W2891069722 magId "2891069722" @default.
- W2891069722 workType "article" @default.